- Home
- ATHA vs MTEX Comparison
ATHA vs MTEX Comparison
Compare ATHA & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- MTEX
- Stock Information
- Founded
- ATHA 2011
- MTEX 1993
- Country
- ATHA United States
- MTEX United States
- Employees
- ATHA N/A
- MTEX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- MTEX Medicinal Chemicals and Botanical Products
- Sector
- ATHA Health Care
- MTEX Health Care
- Exchange
- ATHA Nasdaq
- MTEX Nasdaq
- Market Cap
- ATHA 14.8M
- MTEX 15.8M
- IPO Year
- ATHA 2020
- MTEX 1999
- Fundamental
- Price
- ATHA $4.07
- MTEX $8.75
- Analyst Decision
- ATHA
- MTEX
- Analyst Count
- ATHA 0
- MTEX 0
- Target Price
- ATHA N/A
- MTEX N/A
- AVG Volume (30 Days)
- ATHA 47.2K
- MTEX 22.2K
- Earning Date
- ATHA 11-06-2025
- MTEX 11-11-2025
- Dividend Yield
- ATHA N/A
- MTEX N/A
- EPS Growth
- ATHA N/A
- MTEX N/A
- EPS
- ATHA N/A
- MTEX N/A
- Revenue
- ATHA N/A
- MTEX $112,975,000.00
- Revenue This Year
- ATHA N/A
- MTEX N/A
- Revenue Next Year
- ATHA N/A
- MTEX N/A
- P/E Ratio
- ATHA N/A
- MTEX N/A
- Revenue Growth
- ATHA N/A
- MTEX N/A
- 52 Week Low
- ATHA $2.20
- MTEX $7.22
- 52 Week High
- ATHA $8.26
- MTEX $16.49
- Technical
- Relative Strength Index (RSI)
- ATHA 74.28
- MTEX 49.46
- Support Level
- ATHA $4.01
- MTEX $8.70
- Resistance Level
- ATHA $4.59
- MTEX $10.00
- Average True Range (ATR)
- ATHA 0.30
- MTEX 0.61
- MACD
- ATHA -0.05
- MTEX 0.03
- Stochastic Oscillator
- ATHA 47.32
- MTEX 23.90
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.